Clareo Health | A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification
A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
The decision was taken to halt study enrollment with Cohort #3 in Phase Ib. Therefore, activities for the planned Phase II were not initiated.
This decision to stop further development of this combination was taken due to the challenge for enrollment in this very rare patient population along with the rapidly evolving disease landscape setting.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Locally advanced or metastatic NSCLC
EGFR mutation (L858R and /or ex19del)
cMET amplification by FISH (GCN ≥ 6),
Acquired resistance to EGFR TKI (1st or 2nd generation)
ECOG performance status (PS) ≤ 1.
You may not be if
Prior treatment with 3rd generation TKI
PhaseII : Prior treatment with any of the following agents:
* Crizotinib, or any other cMET inhibitor or HGF-targeting inhibitor.
* Concomitant EGFR TKI and platinum based chemotherapy as first line regimen.
* Platinum-based chemotherapy as first line treatment
